Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol
Authors:
- Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE)CDClinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE)
- Giovanni Fm StrippoliGSGiovanni Fm Strippoli
Open Access
- 9 June 2010
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 11 (1) , 70
Abstract
Anemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are commonly used to increase hemoglobin levels in this population. In observational studies, higher hemoglobin levels (around 11-13 g/dL) are associated with improved survival and quality of life compared to hemoglobin levels around 9-10 g/dL. A systematic review of randomized trials found that targeting higher hemoglobin levels with ESA causes an increased risk of adverse vascular outcomes. It is possible, but has never been formally tested in a randomized trial, that ESA dose rather than targeted hemoglobin concentration itself mediates the increased risk of adverse vascular outcomes. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) trial will assess the benefits and harms of a high versus a low fixed ESA dose for the management of anemia in patients with end stage kidney disease.Keywords
This publication has 20 references indexed in Scilit:
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Epoetin requirements predict mortality in hemodialysis patientsAmerican Journal of Kidney Diseases, 2004
- The Italian SF-36 Health SurveyJournal of Clinical Epidemiology, 1998
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- A Disease-Specific Questionnaire for Assessing Quality of Life in Patients on HemodialysisNephron, 1992
- Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trialsBlood Pressure, 1992